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Abstract
Germinal centers (GC) are sites of intense B cell proliferation, central for T cell dependent
antibody responses. However, the role of MYC, a key cell cycle regulator, in this process has been
questioned. Here, we identified MYC positive B cell subpopulations in immature and mature GCs,
and show through genetic ablation of Myc that they play indispensable roles in GC formation and
maintenance. The identification of these functionally critical cellular subsets has important
implications for human B cell lymphomagenesis, which mostly originates from GC B cells and
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tfrequently involves MYC chromosomal translocations. As these translocations are generally
dependent on transcription of the recombining partner loci, the MYC positive GC subpopulations
may be at a particularly high risk for malignant transformation.
In response to T cell dependent antigens, antigen-specific B cells are driven into the
germinal center (GC) reaction, which is critical for the generation and selection of memory
B and plasma cells expressing somatically mutated high-affinity antibodies1. GCs are sites
of massive B cell proliferation2. However, despite extensive research on the GC reaction,
the mechanisms driving GC B cell proliferation have remained elusive. An issue of
particular importance is the notion that MYC, a master regulator of cellular proliferation
both in nonhematopoietic and hematopoietic cells including B cells3, 4, does not play a role
in this context5, 6.
The MYC transcription factor was first identified as the cellular homolog of the
transforming determinant carried by the avian myelocytomatosis virus MC297. The
conservation of cellular homologs of viral oncogenes across evolutionary time and species
suggests important roles for these genes in normal cellular physiology7. Indeed, germline
ablation of Myc leads to early (E9-10) embryonic lethality due to widespread failure in
organ and tissue growth8. In the hematopoietic compartment MYC is required at early
developmental stages of both B and T cells in the bone marrow and thymus, respectively4, 9.
Experimental evidence demonstrates that MYC plays a crucial role in regulating cellular
proliferation, apoptosis and differentiation of mammalian cells8. During cell cycle
progression, MYC promotes G0/G1-S transition through the activation of genes encoding
cyclin-dependent kinase (CDK) complex proteins, including Cyclin D2 (Ccnd2), as well as
by the repression of CDK inhibitors10, 11.
Although early studies suggested high levels of MYC transcripts and protein in human and
mouse GC B cells12-14, later work refuted these observations, detecting only low MYC
expression levels in these cells5, 6. According to these studies MYC levels were comparable
or even lower than the ones observed in quiescent follicular (FO) B cells where MYC does
not seem to play a major function3, suggesting a dispensable role for MYC in GC B cell
proliferation. Further support for this hypothesis came from the observation that BCL-6, a
master regulator of GC B cell development15, interacts with the transcription factor MIZ1
(ZBTB17), a known partner of MYC, to suppress CDK inhibitors16, and that BCL-6 itself
can repress MYC transcription17. Moreover, in line with the ability of BCL-6 to inhibit
Ccnd2 expression17, GC B cells predominantly express Cyclin D3 (Ccnd3), which, although
dispensable for GC initiation18, 19, is required for GC maturation and is not controlled by
MYC10, 11.
MYC plays a critical role in the proliferation of most, if not all human B cell lymphomas,
the vast majority of which originate from GC or post-GC B cells as demonstrated by their
somatically mutated immunoglobulin (Ig) genes20-22. Indeed, in the GC microenvironments
rapidly dividing B cells undergo somatic hypermutation (SHM) and class switch
recombination (CSR) in their Ig genes, both of which involve DNA strand breaks22.
Infidelity in these processes increases the probability of oncogenic events such as
chromosomal rearrangements22. The MYC gene itself is frequently involved in chromosomal
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ttranslocations in human GC-derived B cell lymphomas22. Such translocations, seen in
roughly 10% of diffuse large B cell lymphomas (DLBCLs) and almost all cases of sporadic
Burkitt lymphoma, juxtapose MYC and enhancers in the Ig loci, leading to deregulated MYC
expression22. However, clear evidence supports the dependence on gene transcription for the
introduction of somatic mutations by activation-induced cytidine deaminase (AICDA)23, 24.
Thus currently there is an apparent contradiction between the absence of MYC transcription
in GC B cells and the recurrent MYC translocations observed in the human lymphomas
originating from these cells. An attractive hypothesis is that the association of MYC
deregulated expression with GC B cell lymphomagenesis reflects its role in the regulation of
cell proliferation at some stage of the GC reaction.
Here, by performing genetic experiments in the mouse, we found that MYC is expressed in
subsets of GC B cells in both immature and mature GCs, and that these cells play an
essential role in GC formation and maintenance.
RESULTS
MYC target genes are enriched in GC B cells
Conflicting observations were made with respect to MYC expression levels between FO and
GC B cells5, 6, 12-14. We re-evaluated this question by performing gene expression analysis
by quantitative PCR (qPCR) in flow purified splenic FO and GC B cells derived from
previously immunized wild-type mice (Fig. 1a). First, we compared the transcript levels of
genes predominantly expressed in GC versus FO B cells, providing an internal control for
our sorting strategy. Consistent with previous findings15, 22, expression of both Aicda (Aid)
and Bcl6 was significantly increased in GC B cells compared to FO B cells (Fig. 1b). In
contrast, Myc transcripts levels were identical in GC and FO B cells (Fig. 1c), in agreement
with previous studies and supporting the hypothesis that MYC is dispensable in GC B
cells5, 6. However, Myc mRNA is highly unstable25, therefore transcript levels might not
correlate with protein activity25. For that reason we decided to perform gene set enrichment
analysis (GSEA)26 on published gene expression profiles of FO and GC B cells27,
evaluating MYC activity through the enrichment of its target genes, (see Methods for
details). Using a MYC target gene list derived from mouse B cells28, we observed a highly
significant enrichment of MYC induced genes in GC B cells, whereas the converse was true
for genes downregulated by MYC. (Fig. 1d). These observations remained statistically
significant when genes associated with the GO terms proliferation, cell cycle and growth
function were removed from the analysis, arguing against the possibility that the results
simply reflected the high proliferative activity of GC B cells (Fig. 1e). Similar observations
were made using lists of genes containing MYC binding motifs in their promoter, and a gene
set of MYC up-regulated genes obtained through the intersection of MYC ChIP-Seq and
MYC siRNA knockdown data in (GC B cell derived) Burkitt lymphoma lines29
(Supplementary Fig. 1). Thus, although on average Myc mRNA is not expressed at higher
levels in GC than FO B cells, GC B cells display an enrichment of MYC target genes.
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The enrichment of MYC target genes in the absence of increased Myc mRNA levels in the
overall population of GC B cells led us to hypothesize that MYC activity may be restricted
to a fraction of GC B cells. To address this issue, we used a Myc reporter allele,
(MycEGFP)30, in which a MYC-EGFP fusion protein (MYCEGFP) is expressed from the
endogenous Myc locus. By flow cytometry, we observed the appearance of MYC positive
GC B cells early after immunization, reaching roughly 20% of GC B cells by day 4 (Fig.
2a,b), an early time-point of GC development before the onset of strong GC B cell
expansion, (Supplementary Fig. 2). We also observed a population of GC B cells positive
for MYC (~10%) at day 10 after immunization, a time-point that reflects the peak of the GC
reaction (Fig. 2b and Supplementary Fig. 2). Small subsets of non-GC B cells, but not of
plasma cells, expressing low amounts of MYC protein were also present in the immunized
animals (Supplementary Fig. 3 and data not shown). Using the MycEGFP reporter allele
and GC B cell markers, we purified the MYC positive GC B cells as well as their MYC
negative counterparts by flow cytometry on day 4 and day 10 after immunization, and
performed gene expression analysis by qPCR. MYC positive GC B cells isolated on day 10
displayed increased levels of Myc transcripts compared to FO B cells, whereas this was not
the case for the MYC positive GC B cells on day 4 after immunization (Fig. 2c). Yet, the
amount of MYCEGFP in day 4 MYC positive GC B cells were higher than in their day 10
counterparts, likely reflecting the impact of post-transcriptional control on MYC protein8
(Supplementary Fig. 3). A further analysis of the day 4 MYC positive GC B cells revealed
a three-fold decrease of Bcl615 mRNA compared to FO B cells (Fig. 2d), whereas the
transcript expression of other GC B cell genes, namely Mybl1 (A-myb)31 and Aicda22 was
strongly increased (~20 and 50-fold respectively; Fig. 2d). Compared to FO B cells there
was also an increase in the load of somatic mutations in the Ig heavy chain (IgH) variable
(V) region gene rearrangements in day 4 MYC positive GC B cells (Fig. 2e). The load of
somatic mutations and the fraction of cells carrying these mutations in their IgH V region
genes was further increased in day 4 MYC negative GC B cells as well as both MYC
positive and negative GC B cells from day 10 immunized mice (Fig. 2e). In addition, these
GC B cell subpopulations demonstrated markedly elevated transcript expression of Bcl6,
Mybl1 and Aicda in comparison to FO and day 4 MYC positive GC B cells (Fig. 2d,e).
Hence, using a MycEGFP reporter allele that allows the visualization of MYC protein in
single cells, we identified distinct subpopulations of MYC positive and negative GC B cells
in both immature and mature GCs.
Early GC B cells express MYC and BCL-6
Following antigen binding and activation via the B cell receptor, B cells migrate to the T-B
cell border where they are co-stimulated through interaction with cognate T helper cells2, 32.
Upon productive T-B cell interaction, B cells migrate back to the intra-follicular B cell area
(~4 days after initial antigen encounter) where they undergo massive expansion in the
environment of follicular dendritic cells (FDCs), forming clusters of proliferating GC B
cells33. BCL-6 is an essential transcription factor for GC B cell formation15, and is required
already at the stage where B cells migrate back into the intra-follicular B cell area34. Given
the fact that early in the GC response MYC positive GC B cells display lower transcript
Calado et al. Page 4
Nat Immunol. Author manuscript; available in PMC 2014 August 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tlevels of the GC B cell genes Bcl6, Mybl1 and Aicda and fewer somatic mutations compared
to their MYC negative counterparts (Fig. 2d,e), we considered the possibility that these
early MYC positive GC B cells represent precursors of the latter. Using
immunofluorescence histology we found through the analysis of spleens of mice 4 days after
immunization that at the very initial stages of GC B cell cluster formation (≤20 cells) the
cells in the clusters are positive for both MYC and BCL-6 (Fig. 3a, and Supplementary
Fig.4a), and that as the number of GC B cells in the cluster increases (>20 cells), B cells
gradually lose MYC expression (Fig. 3b,c, and Supplementary Fig.4b). While both MYC
positive and negative GC B cells expressed the GC B cell typical Ccnd318, 19 (Fig. 3d), the
MYC positive cells also expressed Ccnd2, a direct target of MYC10, 11 (Fig. 3e). Both
Ccnd2 and Ccnd3 are known positive regulators of the cell cycle G0/G1-S transition in B
cells10, 11, 18, 19. Consistently, we found that more than 40% of the MYC positive GC B
cells were at the S-phase of the cell cycle, compared to ~20% of MYC negative GC B cells
(Fig. 3f,g). Taken together these results suggest that early GC B cells are positive for both
MYC and BCL-6, display hyperproliferative properties and give rise to GC B cells positive
only for BCL-6.
MYC is essential for GC formation
To test whether MYC is critical for GC formation, we genetically deleted Myc in GC B cells
at an early stage of the GC reaction3, 35, 36. This resulted in a virtually complete ablation of
GCs in response to T cell-dependent immunization (Fig. 4a, left panel). Analysis of the few
remaining GC B cells present in the Cγ1-cre MycFF hCD2stopFL mice for expression of the
hCD2 reporter showed that these cells had largely escaped cre-mediated recombination (Fig.
4a, right panel, and Supplementary Fig. 5). Impairment of GC B cell formation upon Myc
ablation was further confirmed analyzing additional GC B cell markers by histology and
immunohistochemistry (Fig. 4b). Ablation of Myc in GC B cells interfered with the GC
reaction from early on after immunization, consistent with the observed expression of MYC
at the initiation of the GC response (Fig. 4c). It also prevented B cells from participating in
GC responses in Peyer's patches in the absence of intentional immunization, as evident from
the strong counter-selection of GC B cells expressing the hCD2 reporter in Peyer's patch
GCs, in which the Cγ1-cre transgene induces cre-mediated recombination in approximately
30 to 40% of the GC B cells in control animals35 (Fig. 4d). We conclude that MYC plays an
essential role in both induced and spontaneous GC formation.
BCL-6 fails to rescue GC formation upon MYC ablation
It has been proposed that BCL-6 plays a role in GC B cell proliferation through
transcriptional repression of CDK inhibitors via the interaction with MIZ1, a known partner
of MYC16. We therefore decided to test whether prematurely enhanced Bcl6 expression
could rescue the formation of GCs upon Myc ablation. To address this issue, we ectopically
expressed Bcl6 using the IμBCL6 allele, in which a mouse Bcl6 cDNA is inserted
downstream of the Iμ promoter in the IgH locus, leading to transgenic Bcl6 expression from
early stages of B cell development onwards37. Although expression of Bcl6 from the
IμBCL6 allele was shown to be sufficient to rescue the differentiation of GC B cells in the
spleens of Bcl6 deficient mice37, this was not the case upon conditional ablation of Myc
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t(Fig. 5a, and Supplementary Fig. 6a). Similarly, ectopic Bcl6 expression was unable to
rescue spontaneous GC formation in Peyer's patches of Cγ1-cre MycFF hCD2stopFL mice
(Supplementary Fig. 6b,c). The deficiency in induced and spontaneous GC formation upon
Myc ablation could also not be rescued by ectopic Bcl2 expression38, emphasizing an
essential role for MYC in the development of GC B cells (Supplementary Fig. 6a,b,d,e). In
contrast, concomitant ablation of the endogenous Myc gene and enforced expression of MYC
from a new ROSA26 allele, termed MYCstopFL, was able to fully rescue GC formation (Fig.
5b,c and Supplementary Fig. 5 and 6a,b) as well as IgG1 production (Fig. 5d and
Supplementary Fig. 6f). These results demonstrate that MYC plays a non-redundant role in
the initiation of GC formation.
Mature MYC+ GC B cells localize to the light zone
Early histological observations using light microscopy suggested the compartmentalization
of mature GCs in two morphologically distinct areas: a ‘dark’ zone (DZ), adjacent to the T
cell zone, and a ‘light’ zone (LZ) contiguous to the splenic marginal zone or to the lymph
node capsule39. The ‘lighter’ and ‘darker’ appearances of the GC LZ and DZ respectively,
derive from the fact that B cells in the LZ are scattered amongst a network of FDCs, which
are largely absent from the DZ2. In an attempt to better characterize the population of
mature MYC positive GC B cells, we performed antibody staining for markers that allow the
discrimination of B cells in the DZ and LZ of the GC2, 40. Using flow cytometry we found
that the vast majority of MYC positive GC B cells had lower levels of CXCR4 and higher
levels of CD83, compared to their MYC negative counterparts (Fig. 6a). In agreement we
found, by histology and immunofluorescence, MYC positive GC B cells to be interspersed
amongst FDCs (Fig. 6b,c and Supplementary Fig.7a-c). These observations lead us to
conclude that the majority of the MYC positive GC B cells in mature GCs localize to the
LZ. Consistent with the notion that in the LZ a fraction of GC B cells undergoes T cell-
mediated activation40, the MYC positive mature GC B cells displayed a phenotype
characteristic of recently activated lymphocytes. This phenotype included increased surface
expression of the activation markers CD86, CD83, CD40, CD69 and MHCII (Fig. 6d,e and
Supplementary Fig.7d) and increased transcripts for the ‘immediate early’ genes IκBa
(Nfkbia, indicating NF-κβ activity) and Myc itself (Fig. 6f and 2c). Consistent with increased
NF-κβ activity41, Irf4 expression was also elevated in the MYC positive GC B cells (Fig.
6g), whereas Bcl6 was downregulated (Fig. 2d). This is in agreement with the idea that
CD40 activation signals delivered to B cells by T cells in the LZ direct them to class-
switching42 and inhibit Bcl6 expression43. The MYC positive GC B cells also displayed an
enrichment of MYC target genes compared to their MYC negative counterparts (Fig. 6h and
Supplementary Fig. 7e). Taken together, MYC positive GC B cells in mature GCs mainly
localize to the LZ and display an activated phenotype.
MYC positive GC B cells are required for GC maintenance
As a key function of MYC is to promote G0/G1-S transition10, 11, we assessed whether
mature GC B cells positive for MYC display a proliferative phenotype. Indeed, we found
increased mRNA levels for both Ccnd2 and Ccnd3 in these cells, compared to FO B cells
(Fig. 7a). In contrast, MYC negative GC B cells showed increased levels only of Ccdn3
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t(Fig. 7a). DNA labeling and flow cytometry demonstrated that a considerable fraction
(~38%) of the MYC positive GC B cells were in the S phase of the cell cycle, while this was
the case for ~20% of their MYC negative counterparts (Fig. 7b,c). Given the proliferative
phenotype of MYC positive GC B cells in mature GCs we decided to assess whether MYC
also plays an essential role in the GC maintenance. To this end we devised an experimental
cell transfer system, which allowed us to conditionally ablate Myc in mature GC B cells. For
that we used CD19 knockout mice (CD19KO), in which GC B cells do not develop44, as
recipients for mature B cells. Donor cells were derived from mice carrying a hCD2stopFL
reporter allele either alone or together with a conditional Myc allele (MycF), in combination
with the Mx-cre transgene45. Following cell transplantation, recipient mice were immunized
and subsequently treated with Poly(I:C) at the peak of GC B cell formation to achieve cre-
mediated recombination in the progeny of the transferred B cells. In control mice we
observed a robust GC response following immunization, and cre-mediated recombination
was detected in 40 to 50% of mature GC B cells derived from B cells of mice carrying the
hCD2stopFL allele alone, as measured by hCD2 surface expression (Fig. 7d, upper panel). In
contrast, there was a reduction of ~50% in the total fraction of GC B cells when the donor
cells were derived from mice carrying the MycF allele, and only ~3% of the GC B cells were
positive for hCD2 (Fig. 7d, lower panel). These results indicate massive counter-selection of
MYC deficient mature GC B cells and suggest that Myc expression in mature GC B cells is
required for the perpetuation of the GC reaction. We conclude that mature GC B cells go
through a stage in the LZ at which MYC is essential for their maintenance and that of the
GC.
DISCUSSION
In the present work we re-evaluated the role of the transcription factor MYC, a master
regulator of cellular proliferation, in GC B cell physiology. This unresolved problem derives
from the conflicting observations that GC B cells have one of the fastest rates of cell
division known in mammals2, while the average level of MYC transcripts in these cells is
similar to those of quiescent FO B cells3, 5, 6. We found that, whereas the analysis of bulk
GC B cells indeed did not show an increase in Myc transcript levels versus FO B cells,
analysis of MYC protein at the single cell level revealed the presence of hyperproliferative
MYC positive subpopulations of GC B cells in both immature and mature GCs, essential for
the formation and maintenance of GCs.
Using a conditional knockout approach, we show that ablation of Myc at an early stage of
GC B cell development leads to a complete absence of GC formation. Furthermore, MYC
protein is expressed at the initiation of GC B cell cluster formation, preceding the phase of
massive GC B cell expansion in the intra-follicular B cell area. At this stage we did not
detect increased Myc transcript expression compared to FO B cells. This discrepancy likely
reflects mechanisms of post-transcriptional control of MYC protein8, and the fact that
enhanced Myc transcription is an early transitory event peaking at ~2 hours after the
activation of B cells, preceding the increase in RNA synthesis and DNA replication25.
Repression by BCL-6 may further restrain Myc transcription17, 46. This may be desirable,
because AICDA, essential in GC B cells for antibody repertoire diversification, can target
transcriptionally active genes outside the Ig loci22-24 and promote their translocation24.
Calado et al. Page 7
Nat Immunol. Author manuscript; available in PMC 2014 August 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tIn mature GCs, however, we identified another subset of GC B cells displaying increased
MYC transcripts and protein levels and localizing predominantly to the LZ. Identical
observations were made in human GCs46. These cells show features of cellular activation
and may represent the fraction of GC B cells in the LZ undergoing T cell mediated
activation to reenter the DZ. In agreement, we detected in MYC positive mature GC B cells
activation of the NF-κB pathway and elevated transcript levels of target genes of this
pathway, namely Myc47 itself and Irf442, whereas Bcl643 was downregulated. In addition,
the hyperproliferative phenotype of the MYC positive mature GC B cells, many of which at
the G2/M stage of the cell cycle which is known to largely segregate to DZ GC B cells40,
together with the strong impact of acute Myc ablation on the total fraction of GC B cells
suggests that MYC positive mature GC B cells are poised for DZ re-entry and perpetuation
of the GC reaction, an hypothesis further supported by the experiments of Dominguez-Sola
et al.46.
The transcription factor BCL-6 is essential for the development of GC B cells15. Detailed
examination of the relation between BCL-6 and cellular proliferation led the hypothesis that
GC B cells display an alternative, MYC-independent cell cycle program16. Along these
lines, BCL-6 interacts with the transcription factor MIZ1, a MYC partner, to suppress CDK
inhibitors, and MYC transcription is repressed by BCL-616, 17, 48. In addition BCL-6 inhibits
the expression of Ccnd217, a MYC target, and Ccnd3, which is not controlled by MYC10, 11,
is prominently expressed in GC B cells18, 19. Our studies reveal that at early stages of GC
formation MYC positive GC B cells express both Ccnd2 and Ccnd3, which possibly
contributes to their hyperproliferative phenotype, and that a similar pattern of expression of
these genes is observed in mature GC B cells when they upregulate MYC. The cyclic
dependence of GC B cell proliferation on MYC activity likely reflects a process termed
“cyclic re-entry”, in which step-wise antibody affinity maturation takes place through
multiple rounds of selection40, 49. In this setting, the function of MYC in the GC reaction
may be to induce ‘competence’25 for GC B cell division to occur, i.e. to decide whether a
GC B cell enters a phase of proliferative expansion.
Our work has direct implications for the understanding of the pathogenesis of human GC B
cell derived lymphomas carrying MYC and Ig chromosomal translocations, seen in almost
all sporadic Burkitt lymphomas and ~10% of DLBCLs22. B cell lymphomas, the most
common type of human lymphoid malignancies overall, mostly originate either from GC B
cells or B cells that have passed through the GC reaction22. In the GC microenvironment, B
cells undergo processes of DNA mutation (SHM) and recombination (CSR) in their
immunoglobulin genes while rapidly dividing, and infidelity in these processes leads to an
increased frequency of oncogenic genetic lesions20-22. AICDA, the enzyme responsible for
both SHM and CSR, participates in the formation of chromosomal breaks in the MYC gene
locus that lead to MYC and Ig translocations, and MYC transcription is required for this
process23, 24. In this study we identified in the mouse subpopulations of GC B cells for
which Myc transcription and activity is functionally critical. Identical MYC positive GC B
cell subsets were also found in the human46. Given the mechanism of MYC and Ig
chromosomal translocations, these GC B cell subsets may be prone to undergo the latter
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tevent and thus represent a stage of GC differentiation with a particularly high risk for
malignant transformation.
ONLINE METHODS
Ethics statement
All animal care and procedures followed NIH guidelines and were approved by the IACUC
(03341) of Harvard University and the Immune Disease Institute, and of the Max Delbrück
Center for Molecular Medicine.
Generation of transgenic mice
MYC transgenic mice (MYCstopFL), were generated by targeting the ROSA26 locus using a
construct encoding the human MYC cDNA, preceded by a loxP flanked STOP cassette and
marked by a signaling deficient truncated version of human CD2 (hCD2) under the control
of a internal ribosomal entry site (IRES) downstream of the inserted cDNA. Transgene
transcription is controlled by the CAG promoter. hCD2 reporter transgenic mice
(hCD2stopFL), were generated following the same procedures as for MYCstopFL, whereas
hCD2 cDNA was used and transgene transcription is controlled by the endogenous ROSA26
promoter. C57BL/6 mouse embryonic stem cells (Artemis pharmaceuticals) were used
following described procedures50.
Genetic systems to monitor, ablate or induce MYC expression
MYC expression was monitored using the (MycEGFP)30 allele in which the endogenous Myc
locus encodes a MYC fusion protein with EGFP. For conditional Myc ablation and/or
enforced MYC expression we used a Myc conditional loss-of-function allele (MycF)3 and/or
a newly generated ROSA26 allele, termed MYCstopFL. Conditional activation of the
MYCstopFL allele by cre-mediated recombination is traced by expression of hCD2. To report
cre-mediated recombination in cells carrying the MycF allele, we combined it with a novel
ROSA26 reporter allele hCD2stopFL. For targeted conditional Myc mutagenesis, we used
either the Cγ1-cre transgene35, or Mx-cre, where cre expression is under the control of an
interferon-responsive promoter element45. For enforced Bcl6 expression, we used an allele
that mimics a chromosomal translocation found in DLBCL (IμBCL6)37. EmuBCL-2 mice
were used for ectopic Bcl-2 expression38. Mice carrying either the Cγ1-cre or the Mx-cre
transgenes in combination with the hCD2stopFL allele served as controls.
Immunization and acute Myc deletion
For T cell dependent immunization, eight- to 10-week-old mice were injected i.v. with
1×109 SRBCs (Cedarlane) in PBS. To induce acute Myc deletion in mature GC B cells,
10×106 CD43neghCD2neg splenic B cells from either Mx-cre hCD2stopFL or Mx-cre MycFF
hCD2stopFL mice were transferred into CD19KO mice by i.v. injection. Mice were
immunized the next day with SRBCs and given i.p. injections of 300μg of polyinosinic-
polycytidylic acid (pIpC; Amersham Biosciences), at day 7 and 10 after immunization. GCs
were analyzed at day 13 after immunization.
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tFlow cytometry
Single-cell suspensions were stained with the antibodies described bellow. To exclude dead
cells we used Topro3 (Invitrogen). Samples were acquired on a FACSCanto II (BD) using
FACSDiva software (BD), and analyzed using FlowJo software (Tree Star).
Flow cytometry antibodies
Antigen Clone Company
Mouse_CD19 ID3 BD pharmigen
Mouse_CD95 Jo2 BD pharmigen
Mouse_CXCR4 2B11 BD pharmigen
Mouse_GL7 GL7 BD pharmigen
Mouse_CD40 3/23 BD pharmigen
Mouse_CD38 90 eBioscience
Mouse_CD93 AA4.1 eBioscience
Mouse_MHCII M5/114.15.2 eBioscience
Mouse_B220 RA3-6B2 eBioscience
Mouse_CD69 H1.2F3 eBioscience
Human_CD2 TS1/8 Biolegend
Mouse_CD83 Michel-19 Biolegend
Mouse_CD21 7E9 Biolegend
Mouse_CD23 B3B4 Biolegend
ELISA and SRBC-specific antibody detection
These analyses were performed following described procedures36.
Quantitative RT-PCR
These analyses were performed following described procedures36. Primer sequences are
described bellow. At least 3 biological samples were assayed in triplicate.
Primers sequences
Bcl6 5′-GCCCACGTTCCCGGAGGAGA-3′
5′-CGTCTGCAGCGTGTGCCTCT-3′
IkBa 5′-TTGGTCAGGTGAAGGGAGAC-3′
5′-GCTTTCAGAAGTGCCTCAGC-3′
Irf4 5′-AGGTCTGCTGAAGCCTTGGC-3′
5′-CTTCAGGGCTCGTCGTGGTC-3′
MybL1 5′-AGCGCCTGGGAAACCGTTGG-3′
5′-GCCCTCCTGTTCCACTTTTCTTCGC-3′
Ccnd2 5′-TCGCAAGCTGCCCCAGCAAA-3′
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5′-GGCTGCTCCCACGCTTCCAG-3′
Aicda 5′-TAGTGCCACCTCCTGCTCACT-3′
5′-CAACAATTCCACGTGGCAGCC-3′
Ccnd3 5′-CGGCGGGGTTGTGATCACTCG-3′
5′-TCCTGCGATGGCTCACGGGT-3′
Myc 5′-GCCAGCCCTGAGCCCCTAGT-3′
5′-GGGCTGTGCGGAGGTTTGCT-3′
Hprt 5′-GTCATGCCGACCCGCAGTC-3′
5′-GTCCTGTCCATAATCAGTCCATGAGGAATAAAC-3′
Histology and immunofluorescence
Spleens were fixed with 10% formalin (Sigma), paraffin-embedded and sections stained
with hematoxylin (Sigma) and PNA (Vector). For immunofluorescence spleens were
embedded in OCT (Sakura) and flash frozen in liquid nitrogen. Tissue sections were cut on a
CM3050s cryostat (Leica), fixed in 4% paraformaldehyde (Sigma), and stained with the
antibodies described bellow. Images were acquired with a Nikon Ti-E inverted microscope
(Nikon) using Slidebook (3i) and visualized with Photoshop (Adobe). We performed the
scoring of MYC and BCL-6 positivity in individual GC B cell clusters using single
fluorescence channels and the “Cell Counter” plug-in in ImageJ software (http://
imagej.nih.gov/ij/).
Immunofluorescence antibodies
Antigen Clone Company
Mouse/Human_BCL-6 sc-C19 Santa Cruz
Mouse/Human_MYC Y69 Epitomics
Mouse_BCL-6 mGI191 E eBioscience
Mouse_CD3 145-2C11 BD pharmigen
Mouse_CD35 8C12 BD pharmigen
B cell DNA content and IgH somatic mutation
These analyses were performed following described procedures36.
Microarray
Gene expression profiling was performed for 2 biological replicates of flow sorted
MYCEGFP positive and negative GC B cells of 10 day SRBC immunized MycEGFP mice
using the mouse WG-6 v2.0 Expression BeadChip array (illumina).
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Data were analyzed using Wilcoxon-Mann-Whitney test; a p value ≤0.05 was considered
significant. A single asterisk (*) in the graphs of figures represents a p value ≤0.05, double
asterisks (**) a p value ≤0.01, and triple asterisks (***) a p value ≤0.001, and “ns” stands
for not statistically significant, i.e., a p value >0.05. Data in figures are represented as mean
± standard error of the mean (SEM). Prism (GraphPad) was used for statistical analysis.
Gene set enrichment analysis
Gene set enrichment analysis (GSEA)26 was done using the Broad Institute Java
implementation code. MYC associated gene-sets YU_CMYC_UP, YU_CMYC_DN, V
$MYC_Q2 and V$MYCMAX_B from the Broad Institute MSigDB were analyzed using the
signal-to-noise ratio as ranking measure, and gene labels were permuted 1000 times for NES
and FDR estimation. Array data for FO and GC B cells was from GEO:GSE15907
(ImmGen), raw data was processed with RMA background correction and quantile
normalization. To create a high-confidence set of MYC up-regulated genes in the Burkitt
Lymphoma context we curated the MYC ChIP-Seq peak regions from Seitz et al.29 as
follows: only peak regions with mus-musculus orthologous regions and a FDR <1e-4 where
considered. After gene annotation of the filtered peak regions, only genes showing
significant downregulation (adjusted p value ≤0.05 and Log2(FC) ≤-0.5) in three Burkitt
Lymphoma cell lines (via MYC siRNA29) were considered to be functional targets of MYC.
This gene set was used for GSEA testing of the FO and GC B cell (GEO:GSE15907) and of
MYCEGFP positive and negative GC B cells (GEO:GSE39443) gene expression profiles.
The latter was also used for GSEA testing for the MYC gene sets YU_CMYC_UP,
YU_CMYC_DN.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. MYC target genes are enriched in GC B cells
(a) Flow cytometry analysis and gating strategy for flow sorting of splenic GC B cells
(B220posCD38lowCD95high) and FO B cells (B220posCD38highAA4.1negCD21posCD23high)
of 10 day SRBC immunized (D10 SRBCi) C57BL/6 wild-type mice. (b) Real-time PCR
analysis of Bcl-6 and Aicda mRNA of flow sorted GC (green) and FO (black) B cells. Data
are presented relative to Hprt and normalized to FO B cells, (mean and s.e.m. of triplicates).
(c) Real-time PCR analysis of Myc mRNA as in (b). Data are presented as in (b). (d) GSEA
of FO and GC B cell gene expression profiles for the MYC up-regulated
(YU_MYC_TARGETS_UP, left panel) and downregulated
(YU_MYC_TARGETS_DOWN, right panel) gene sets. (e) GSEA of FO and GC B cell
gene expression profiles for MYC up-regulated (left panel) and downregulated (right panel)
gene sets, as in (d) upon removal of genes, from those gene sets, whose GO-terms contain,
‘proliferation’, ‘cell cycle’ or ‘growth’, MINUSPROLGENES. FO and GC B cell gene
expression profiles (GEO:GSE15907, ImmGen). See Methods for GSEA analysis details.
Data are representative of 3 independent experiments (a-c). ns, not statistically significant. *
p≤0.05, ** p≤0.01, *** p≤0.001.
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tFigure 2. A fraction of both newly formed and mature GC B cells is positive for MYC
(a) Flow cytometry analysis of splenic GC B cells for MYCEGFP expression of 4 day SRBC
immunized (D4 SRBCi) C57BL/6 wild-type mice and of MycEGFP mice either not-
immunized, 2 day (D2 SRBCi) and 4 day (D4 SRBCi) SRBC immunized. (b) Flow
cytometry as in (a) of 10 day SRBC immunized (D10 SRBCi) C57BL/6 wild-type and
MycEGFP mice. Right panel, graphical representation of the frequency of MYCEGFP positive
cells within GC B cells of D4 SRBCi and D10 SRBCi MycEGFP mice (c) Real-time PCR
analysis of Myc mRNA of flow sorted FO and of day 4 MYCEGFP positive (D4P) and
negative (D4N) GC Bcells, and day 10 MYCEGFP positive (D10P) and negative (D10N) GC
B cells. Data are presented relative to Hprt and normalized to FO B cells, (mean and s.e.m.
of triplicates). (d) Real-time PCR analysis of Bcl6, Mybl1 and Aicda mRNA as in (c). Data
are presented as in (c). (e) Igh somatic mutation of FO B cells and D4P, D4N, D10N, D10P
GC B cells. Numbers in the center of the pie-chart represent sequences analyzed, and in each
pie-chart section the number of mutations. Data are representative of at least 3 (a,b), 5
independent experiments (c,d), and of 3 mice (f). ns, not statistically significant. * p≤0.05,
** p≤0.01, *** p≤0.001.
Calado et al. Page 17
Nat Immunol. Author manuscript; available in PMC 2014 August 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 3. Early GC B cells express both MYC and BCL-6 and are hyperproliferative
(a) Representative image of histological immunofluorescence analysis of spleen of 4 day
SRBC immunized (D4 SRBCi) C57BL/6 wild-type mice. T cells (CD3, green), FDCs
(CD35, Blue), BCL-6 (white), MYC (red), cut-off of ≤20 BCL-6 positive cells per FDC
area. (b) Representative image as in (a), cut-off of >20 BCL-6 positive cells per FDC area
(c) Graphical representation of the fraction of BCL-6 and MYC double positive cells as
function of BCL-6 positive cell count per FDC area. Data of GCs of D4 SRBCi (D4) and
D10 SRBCi (D10) C57BL/6 wild-type mice. Each red symbol represents the analysis of one
FDC area. Red line represents non-linear regression curve fit assuming an one-phase decay.
Dashed line represents 95% confidence interval. (d) Real-time PCR analysis of Ccnd3
mRNA, of flow sorted FO and of day 4 MYCEGFP positive (D4P) and negative (D4N) GC B
cells. Data are presented relative to Hprt and normalized to FO B cells, (mean and s.e.m. of
triplicates). (e) Real-time PCR analysis of Ccnd2 mRNA, as in (d). Data are presented as in
(d). (f) Flow cytometry analysis of the DNA content of non-GC B cells, and of D4P and
D4N GC B cells. (g) Graphical representation of the data presented in (f), (mean and s.e.m.).
Scale bar 25μm (a, b). Data are representative of at least 3 (a-c,f,g) and 5 (d,e) independent
experiments. ns, not statistically significant. * p≤0.05, ** p≤0.01, *** p≤0.001.
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tFigure 4. MYC is essential for GC formation
(a) Flow cytometry analysis of splenic GC B cells of 10 day SRBC immunized (D10
SRBCi) mice of the indicated genotypes, right panel analysis of reporter (hCD2) positive
GC B cells. (b) Representative images of histological immunohistochemical analysis of
spleen of D10 SRBCi mice of the indicated genotypes. PNA (brown) and hematoxylin as
counterstain. (c) Graphical representation of flow cytometry data of splenic hCD2 positive
GC B cells of mice of the indicated genotypes, either not immunized or 5 and 10 days after
SRBC immunization. (d) Flow cytometry analysis of peyer's patch GC B cells of mice of the
indicated genotypes, right panel analysis of hCD2 positive GC B cells. Scale bar 25μm (b).
Data are representative of at least 3 independent experiments (a-d). ns, not statistically
significant. * p≤0.05, ** p≤0.01, *** p≤0.001.
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tFigure 5. Enforced Bcl6 expression fails to rescue GC formation upon Myc ablation
(a) Flow cytometry analysis of splenic GC B cells of 10 day SRBC immunized (D10
SRBCi) mice of the indicated genotypes, lower panel, analysis of reporter (hCD2) positive
GC B cells. (b) Flow cytometry analysis as in (a), of mice of the indicated genotypes, right
panel as in (a). (c) Representative images of histological immunohistochemical analysis of
spleen of D10 SRBCi mice of the indicated genotypes. BCL-6 (dark blue). (d) Graphical
representation of flow cytometry measured anti-SRBC specific IgG1 serum antibodies at
D10 SRBCi, (mean and s.e.m.), Low ctrl, unimmunized mice, High ctrl, serum from mice
hyperimmunized. Scale bar 25μm (c). Data are representative of at least 3 independent
experiments (a-c) and of 4 mice (d).
Calado et al. Page 20
Nat Immunol. Author manuscript; available in PMC 2014 August 14.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 6. MYC positive GC B cells in mature GCs localize to the light zone and display an
activated phenotype
(a) Flow cytometry analysis of splenic MYCEGFP negative (D10N) and positive (D10P) GC
B cells of 10 day SRBC immunized (D10 SRBCi) MycEGFP mice. DZ, dark zone; LZ, light
zone. (b) Representative image of histological immunofluorescence analysis of spleen of
D10 SRBCi C57BL/6 wild-type mice. FDCs (CD35, Blue), BCL-6 (white), MYC (red). (c)
Inset, dark zone and light zone boundary, white dashed line. White arrows, MYC positive
cells. (d) Graphical representation of flow cytometry analysis of CD86, CD83 expression of
non-GC B cells, and of D10N and D10P GC B cells. gMFI, geometrical mean fluorescence
intensity, (mean and s.e.m.) (e) Graphical representation as in (d) of CD40, CD69 and
MHCII expression. Data are presented as in (d). (f) Real-time PCR analysis of IγBa mRNA
of flow sorted FO B cells and of D10N and D10P GC B cells. Data are presented relative to
Hprt and normalized to FO B cells, (mean and s.e.m. of triplicates). (g) Real-time PCR
analysis of Irf4 mRNA as in (f). Data are presented as in (f). (h) GSEA of D10 MYCEGFP
positive and negative GC B cell gene expression profiles, for the MYC up-regulated
(YU_MYC_TARGETS_UP, left panel) and downregulated
(YU_MYC_TARGETS_DOWN, right panel) gene sets. See Methods for GSEA analysis
details. Scale bar 25μm (c,d). Data are representative 3 (a-c, d,e) and 5 (f,g) independent
experiments. ns, not statistically significant. * p≤0.05, ** p≤0.01, *** p≤0.001.
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tFigure 7. A large fraction of MYC positive mature GC B cells are in cell cycle, and these cells are
essential for GC maintenance
(a) Real-time PCR analysis of Ccdn2 and Ccdn3 mRNA, of flow sorted FO and of day 10
MYCEGFP negative (D10N) and positive (D10P) GC B cells. Data are presented relative to
Hprt and normalized to FO B cells, (mean and s.e.m. of triplicates). (b) Representative
analysis by flow cytometry of the DNA of non-GC B cells and of D10N and D10P GC B
cells. (c) Graphical representation of data presented in (b), (mean and s.e.m.) (d) Flow
cytometry analysis of splenic GC B cells 13 days after SRBC immunization in mice of the
indicated genotypes. Right panel analysis of reporter (hCD2) positive GC B cells. Data are
representative of 5 (a), 3 (b, c) and 2 (d) independent experiments.
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